MedTrace Logo

Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)

NCT02108002 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2018-09-14

No results posted yet for this study

Summary

Background:

\- Von Hippel-Lindau (VHL) disease is a rare gene disease. People with VHL often have a brain tumor called hemangioblastoma. Standard treatment for these tumors is risky surgery. Researchers want to find new ways to treat people who have the tumors. They want to see if a drug that fights other cancers might slow the growth of hemangioblastomas in some people with VHL. Some people with VHL have mutations that make abnormal proteins. Tumors form in such people because the abnormal protein is broken down quickly. The cancer drug may work in these tumors by preventing breakdown of protein.

Objective:

\- To study how the drug vorinostat affects hemangioblastomas in people with VHL.

Eligibility:

\- Adults at least 18 old with hemangioblastomas from VHL.

Design:

* Participants must already be in study 03-N-0164. They must have tumor surgery scheduled.
* Participants must stop taking most medications 14 days before surgery.
* One week before surgery, participants will enter the hospital. They will be screened with medical history and physical and neurological exams. They will give blood and urine samples. Participants will have an electrocardiogram. For this test, small sticky patches are put on the arms, legs, and chest. Participants will lie still for a few minutes while a machine records heart rate and rhythm.
* Participants will take one vorinostat by mouth each day for 7 days.
* Participants will have blood drawn during the week to check for any side effects.
* Participants will have their tumor removed in surgery. Researchers will study the tumor tissue for the effects of the study drug.
* A nurse will call participants 1 month after surgery to check for side effects.

Conditions

  • Von Hippel-Lindau Disease

Interventions

DRUG

Vorinostat

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    lead NIH

Principal Investigators

  • Prashant Chittiboina, M.D. · National Institute of Neurological Disorders and Stroke (NINDS)

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-05
Primary Completion
2018-09-12
Completion
2018-09-12

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02108002 on ClinicalTrials.gov